MX336958B - Metodos y composiciones para modular la hemostasia. - Google Patents
Metodos y composiciones para modular la hemostasia.Info
- Publication number
- MX336958B MX336958B MX2012006836A MX2012006836A MX336958B MX 336958 B MX336958 B MX 336958B MX 2012006836 A MX2012006836 A MX 2012006836A MX 2012006836 A MX2012006836 A MX 2012006836A MX 336958 B MX336958 B MX 336958B
- Authority
- MX
- Mexico
- Prior art keywords
- methods
- hemostasia
- modulate
- compositions
- variants
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
- C12N9/6424—Serine endopeptidases (3.4.21)
- C12N9/6432—Coagulation factor Xa (3.4.21.6)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/482—Serine endopeptidases (3.4.21)
- A61K38/4846—Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
- C12N9/6424—Serine endopeptidases (3.4.21)
- C12N9/647—Blood coagulation factors not provided for in a preceding group or according to more than one of the proceeding groups
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/21—Serine endopeptidases (3.4.21)
- C12Y304/21006—Coagulation factor Xa (3.4.21.6)
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Biomedical Technology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Hematology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Dermatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Enzymes And Modification Thereof (AREA)
- Peptides Or Proteins (AREA)
Abstract
La presente invención se refiere a una variante del Factor Xa que modula la hemostasia que comprende al menos una mutación por substitución en los aminoácidos 41-179 y 235-488 de SEQ ID NO: 1, en donde el Asp en la posición 418 (posición 194 en el sistema de numeración de quimiotripsina) se sustituye con Asn o Glu.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US73668005P | 2005-11-15 | 2005-11-15 | |
PCT/US2006/060927 WO2007059513A2 (en) | 2005-11-15 | 2006-11-15 | Compositions and methods for modulating hemostasis |
Publications (1)
Publication Number | Publication Date |
---|---|
MX336958B true MX336958B (es) | 2016-02-05 |
Family
ID=38049397
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2012006836A MX336958B (es) | 2005-11-15 | 2006-03-21 | Metodos y composiciones para modular la hemostasia. |
MX2008006313A MX2008006313A (es) | 2005-11-15 | 2006-03-21 | Metodos y composiciones para modular la hemostasia. |
MX2012006837A MX337059B (es) | 2005-11-15 | 2008-05-15 | Metodos y composiciones para modular la hemostasia. |
Family Applications After (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2008006313A MX2008006313A (es) | 2005-11-15 | 2006-03-21 | Metodos y composiciones para modular la hemostasia. |
MX2012006837A MX337059B (es) | 2005-11-15 | 2008-05-15 | Metodos y composiciones para modular la hemostasia. |
Country Status (26)
Country | Link |
---|---|
US (4) | US8383386B2 (es) |
EP (4) | EP1948690B1 (es) |
JP (4) | JP5823088B2 (es) |
KR (4) | KR101574042B1 (es) |
CN (1) | CN101356192B (es) |
AU (1) | AU2006315175B2 (es) |
BR (1) | BRPI0618654B1 (es) |
CA (2) | CA2971971A1 (es) |
CR (1) | CR9956A (es) |
DK (1) | DK1948690T3 (es) |
EC (1) | ECSP088452A (es) |
ES (2) | ES2549929T3 (es) |
GT (1) | GT200800065A (es) |
HK (2) | HK1128699A1 (es) |
IL (1) | IL191310A (es) |
MX (3) | MX336958B (es) |
MY (1) | MY162181A (es) |
NO (3) | NO345177B1 (es) |
NZ (1) | NZ568108A (es) |
PL (1) | PL1948690T3 (es) |
PT (1) | PT1948690E (es) |
RU (2) | RU2008123398A (es) |
SI (1) | SI1948690T1 (es) |
SV (1) | SV2008002906A (es) |
WO (1) | WO2007059513A2 (es) |
ZA (1) | ZA200804026B (es) |
Families Citing this family (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
LT3078743T (lt) | 2007-09-28 | 2020-09-25 | Portola Pharmaceuticals, Inc. | Antikūnai xa veiksnio inhibitoriams ir jų naudojimo būdai |
JP5709316B2 (ja) | 2008-11-14 | 2015-04-30 | ポートラ ファーマシューティカルズ, インコーポレイテッド | 第Xa因子阻害剤のための解毒剤および血液凝固剤と組み合わせて該解毒剤を使用する方法 |
EP2414517B1 (en) | 2009-03-30 | 2016-09-21 | Portola Pharmaceuticals, Inc. | Antidotes for factor xa inhibitors and methods of using the same |
CA2767858C (en) | 2009-07-15 | 2019-02-12 | Portola Pharmaceuticals, Inc. | Unit dose formulation of antidotes for factor xa inhibitors and methods of using the same |
EP2624859B1 (en) | 2010-10-06 | 2017-03-01 | Medimmune Limited | Factor ii alone or in combination with further factors for treatment of impaired haemostasis associated with dilutional coagulopathy |
WO2013049804A1 (en) * | 2011-09-30 | 2013-04-04 | The Children's Hospital Of Philadelphia | Compositions and methods for modulating hemostasis |
WO2014018120A1 (en) | 2012-07-25 | 2014-01-30 | Catalyst Biosciences, Inc. | Modified factor x polypeptides and uses thereof |
US20150343034A1 (en) | 2013-01-31 | 2015-12-03 | Pfizer Inc. | Compositions and methods for counteracting factor xa inhibition |
FR3001729B1 (fr) * | 2013-02-04 | 2015-03-06 | Lab Francais Du Fractionnement | Mutants du facteur x |
MY173548A (en) | 2013-09-24 | 2020-02-04 | Pfizer | Fxa variant compositions |
US20160235824A1 (en) * | 2013-11-01 | 2016-08-18 | The Children's Hospital Philadelphia | Compositions and Methods for Increasing the Half-Life of Factor XA |
EP3096779B1 (en) * | 2014-01-24 | 2019-12-18 | Pfizer Inc | Compositions and methods for treating intracerebral hemorrhage |
RS60706B1 (sr) | 2014-05-26 | 2020-09-30 | Academisch Ziekenhuis Leiden | Prohemostatski proteini za lečenje krvarenja |
US10676731B2 (en) | 2014-08-19 | 2020-06-09 | The Children's Hospital Of Philadelphia | Compositions and methods for modulating factor IX function |
CN109789181A (zh) | 2016-07-27 | 2019-05-21 | 费城儿童医院 | 用于调节因子ix功能的组合物和方法 |
WO2023118150A1 (en) | 2021-12-22 | 2023-06-29 | Royal College Of Surgeons In Ireland | A conjugate for use in localising a molecule to the vascular endothelium. |
Family Cites Families (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6093699A (en) | 1987-07-09 | 2000-07-25 | The University Of Manitoba | Method for gene therapy involving suppression of an immune response |
WO1994017810A1 (en) | 1993-02-12 | 1994-08-18 | The Wistar Institute Of Anatomy And Biology | Recombinant cytomegalovirus vaccine |
CA2160583A1 (en) | 1993-04-16 | 1994-10-27 | Stanley A. Plotkin | Recombinant cytomegalovirus vaccine |
WO1995005864A1 (en) | 1993-08-27 | 1995-03-02 | Government Of The United States Of America, Represented By The Secretary Of The Department Of Health And Human Services | Convection-enhanced drug delivery |
AT401270B (de) | 1994-09-26 | 1996-07-25 | Immuno Ag | Verfahren zur quantifizierung von genomischer dna |
US5998205A (en) | 1994-11-28 | 1999-12-07 | Genetic Therapy, Inc. | Vectors for tissue-specific replication |
JP3961019B2 (ja) | 1995-02-28 | 2007-08-15 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | 遺伝子転移媒介の血管形成療法 |
AU2319497A (en) | 1996-03-07 | 1997-09-22 | Regents Of The University Of California, The | Helper-free, totally defective adenovirus for gene therapy |
AT405516B (de) | 1997-02-27 | 1999-09-27 | Immuno Ag | Faktor x-analoge mit modifizierter proteasespaltstelle |
AT405517B (de) | 1997-02-27 | 1999-09-27 | Immuno Ag | Faktor x-deletionsmutanten und analoge davon |
AT410216B (de) * | 1999-08-10 | 2003-03-25 | Baxter Ag | Faktor x-analogon mit verbesserter aktivierbarkeit |
AU2001249389A1 (en) | 2000-03-22 | 2001-10-03 | The Children's Hospital Of Philadelphia | Modified blood clotting factors and methods of use |
FR2831170B1 (fr) * | 2001-10-19 | 2004-03-19 | Inst Nat Sante Rech Med | Proteines c modifiees activables directement par la thrombine |
FR2841904B1 (fr) * | 2002-07-03 | 2004-08-20 | Inst Nat Sante Rech Med | Analogues de facteurs x clivables par la thrombine |
EP1728798A1 (en) | 2005-06-01 | 2006-12-06 | ZLB Behring GmbH | Coagulation factor X polypeptides with modified activation properties |
CN102325880B (zh) * | 2008-12-19 | 2014-10-01 | 国家健康与医学研究院 | 丝氨酸蛋白酶衍生物及其在凝血功能障碍的预防或治疗中的用途 |
-
2006
- 2006-03-21 MX MX2012006836A patent/MX336958B/es unknown
- 2006-03-21 MX MX2008006313A patent/MX2008006313A/es active IP Right Grant
- 2006-11-15 KR KR1020147023791A patent/KR101574042B1/ko active IP Right Grant
- 2006-11-15 JP JP2008541467A patent/JP5823088B2/ja active Active
- 2006-11-15 AU AU2006315175A patent/AU2006315175B2/en active Active
- 2006-11-15 DK DK06846312.4T patent/DK1948690T3/da active
- 2006-11-15 SI SI200631810T patent/SI1948690T1/sl unknown
- 2006-11-15 RU RU2008123398/13A patent/RU2008123398A/ru not_active Application Discontinuation
- 2006-11-15 KR KR1020167004589A patent/KR20160029135A/ko not_active Application Discontinuation
- 2006-11-15 CA CA2971971A patent/CA2971971A1/en not_active Abandoned
- 2006-11-15 CA CA2629491A patent/CA2629491C/en active Active
- 2006-11-15 PT PT68463124T patent/PT1948690E/pt unknown
- 2006-11-15 ES ES11182949.5T patent/ES2549929T3/es active Active
- 2006-11-15 BR BRPI0618654-8A patent/BRPI0618654B1/pt active IP Right Grant
- 2006-11-15 KR KR1020087014386A patent/KR101827569B1/ko active IP Right Grant
- 2006-11-15 PL PL06846312T patent/PL1948690T3/pl unknown
- 2006-11-15 MY MYPI20081594A patent/MY162181A/en unknown
- 2006-11-15 EP EP06846312.4A patent/EP1948690B1/en active Active
- 2006-11-15 NZ NZ568108A patent/NZ568108A/en unknown
- 2006-11-15 KR KR1020137033906A patent/KR101600158B1/ko active Application Filing
- 2006-11-15 CN CN2006800507791A patent/CN101356192B/zh active Active
- 2006-11-15 EP EP11182950.3A patent/EP2431390B1/en active Active
- 2006-11-15 EP EP11182946A patent/EP2431389A1/en not_active Withdrawn
- 2006-11-15 US US12/093,783 patent/US8383386B2/en active Active
- 2006-11-15 EP EP11182949.5A patent/EP2423224B1/en active Active
- 2006-11-15 ES ES06846312.4T patent/ES2496567T3/es active Active
- 2006-11-15 WO PCT/US2006/060927 patent/WO2007059513A2/en active Application Filing
-
2008
- 2008-05-07 CR CR9956A patent/CR9956A/es unknown
- 2008-05-07 IL IL191310A patent/IL191310A/en active IP Right Grant
- 2008-05-12 ZA ZA200804026A patent/ZA200804026B/xx unknown
- 2008-05-13 NO NO20082182A patent/NO345177B1/no unknown
- 2008-05-14 GT GT200800065A patent/GT200800065A/es unknown
- 2008-05-15 MX MX2012006837A patent/MX337059B/es unknown
- 2008-05-15 EC EC2008008452A patent/ECSP088452A/es unknown
- 2008-05-15 SV SV2008002906A patent/SV2008002906A/es not_active Application Discontinuation
-
2009
- 2009-07-17 HK HK09106536.9A patent/HK1128699A1/xx unknown
-
2011
- 2011-07-25 RU RU2011130932/10A patent/RU2570547C2/ru active
-
2012
- 2012-06-21 HK HK12106113.5A patent/HK1165444A1/zh not_active IP Right Cessation
- 2012-12-23 US US13/726,187 patent/US9410137B2/en active Active
-
2013
- 2013-11-14 JP JP2013236348A patent/JP5957167B2/ja active Active
-
2015
- 2015-07-17 JP JP2015143337A patent/JP6236194B2/ja active Active
-
2016
- 2016-08-05 US US15/229,922 patent/US9896676B2/en active Active
-
2017
- 2017-09-04 JP JP2017169887A patent/JP6571735B2/ja active Active
-
2018
- 2018-02-20 US US15/899,609 patent/US20180251745A1/en not_active Abandoned
-
2020
- 2020-06-05 NO NO20200670A patent/NO20200670A1/no unknown
- 2020-06-05 NO NO20200671A patent/NO20200671A1/no unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX336958B (es) | Metodos y composiciones para modular la hemostasia. | |
CY1117833T1 (el) | Νεες συνθεσεις και μεθοδοι για την αγωγη του καρκινου | |
CY1113102T1 (el) | Ενωσεις φαινυλπροπιοναμιδιου και η χρηση αυτων | |
CU20070160A7 (es) | Pirrolopirazoles, inhibidores potentes de quinasa | |
CR10213A (es) | Moduladores de la proteína quinasa aurora | |
NO20092637L (no) | Fremgangsmater for behandling | |
CY2014030I1 (el) | Θεραπευτικες συνθεσεις που περιλαμβανουν ingenol-3-angelate | |
EA200700537A1 (ru) | Триазолофталазины | |
EA201070519A1 (ru) | Соединения тропана | |
CR11373A (es) | COMPUESTOS DE TIENOPIRIMIDINA Y PIRAZOLOPIRIMIDINA Y SU USO COMO INHIBIDORES DE mTOR CINASA Y PI3 CINASA | |
CY2014011I1 (el) | Χορηγηση αναστολεων διπεπτιδυλοπεπτιδασης | |
EA200802008A1 (ru) | Фармацевтические композиции | |
EA200701396A1 (ru) | Триазолофталазины в качестве ингибиторов pde-2 | |
EA201100037A1 (ru) | Органические соединения | |
CR10094A (es) | Carbonilamino pirrolopirazoles, potentes inhibidores de quinasa | |
SV2009003434A (es) | Inhibicion de arni de expresion de alfa-enac | |
CL2008000873A1 (es) | Compuestos derivados de pirrolidin amidas; composicion farmaceutica que comprende dichos compuestos; y su uso para tratar trombosis. | |
UY29853A1 (es) | Derivados de diacilindazol como inhibidores de lipasas y fosfolipasas- | |
BRPI0813000A2 (pt) | Composições terapêuticas e uso das mesmas | |
UY31484A1 (es) | Piperidinas heteroaril-sustituidas | |
BRPI0720211A2 (pt) | Derivado de indanona, composição, e, uso de uma composição | |
EA200870515A1 (ru) | Моноциклические гетероарильные соединения | |
EA200700400A1 (ru) | Производные n-(1h-индолил)-1н-индол-2-карбоксамидов, их получение и их применение в терапии | |
HK1142608A1 (en) | 5-pyridinone substituted indazoles and pharmaceutical compositions thereof 5- | |
PA8630801A1 (es) | Nuevos imidazoles |